Search academic texts

Registration Number

0224U002962, 0123U100711 , R & D reports

Title

To develop a method of antitumor therapy of primary malignant bone tumors, based on magnetochemical technology using nanocomplexes

Head

Orel Valerii E., Доктор біологічних наук

Registration Date

19-03-2024

Organization

National Cancer Institute

Description

 Research object - human osteosarcoma cells Saos-2 line; liposomal and free form of doxorubicin, radiofrequency electromagnetic radiation. Equipment - apparatus for local short-wave induction heating “Magniterm” (Radmir), flow cytometer Dxflex (Beckman Coulter), binocular microscope, Primostar (Carl Zeiss, Germany). The purpose of the work is to improve the effectiveness of complex treatment of patients with high-grade malignant bone sarcomas. Research methods - laboratory, computer modeling, bioengineering, physicochemical and statistical. The design of the “Magniterm” apparatus was determined and the parameters of electromagnetic radiation were selected according to computer modeling using COMSOL Multiphysics 5.6 software for stand-alone in vitro studies of human osteosarcoma cells Saos-2. Experiments with osteosarcoma cells in vitro indicate the following main features of the action of liposomal doxorubicin and the combined effect with electromagnetic radiation. Increasing the incubation time of cells from 48 to 72 hours in the presence of liposomal doxorubicin led to an increase in its cytotoxic activity by 79% (p <0.05). The degree of accumulation of doxorubicin by Saos-2 cells with the combined action of liposomal doxorubicin and electromagnetic radiation after 48 hours of incubation was higher by 69% (p <0.05) compared to the action of the free form of the drug and electromagnetic radiation. The combined effect of liposomal doxorubicin and electromagnetic radiation on Saos-2 cells increased the induction of early apoptosis to 12% (p <0.05) compared to the independent action of the drug, the number of active oxygen species by 23% (p <0.05) and the level of expression of Bax proteins by 107% (p <0.05) compared to the control.

Product Description

popup.authors

Diedkov Anatolii H.
Dasiukevych Olha Yo.
Ostafiichuk Vasyl V.
Rykhalskyi Oleksandr Yu.